Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 12/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL34819 | 0.98 | FDPS (0.40) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL16473574 | 0.95 | FDPS (0.41) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34271 | 0.94 | FDPS (0.40) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34668 | 0.90 | FDPS (0.41) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Trifluoromethanesulfonic Acid SCHEMBL34736 | 0.89 | FDPS (0.39) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL34733 | 0.88 | FDPS (0.38) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL13866471 | 0.88 | FDPS (0.43) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34147 | 0.87 | MEN1 (0.48) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL34626 | 0.85 | KDM4E (0.41) | FDPSMEN1KMT2AKDM4E | |
| Trifluoromethanesulfonic Acid SCHEMBL34787 | 0.85 | FDPS (0.40) | FDPSMEN1HSP90AA1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| CN-118843914-A | Solid electrolytic capacitor and method for manufacturing the same | 佳里多股份公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024055011-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-2473277-B1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION OR ACID-FUNCTIONALIZED IONIC LIQUID | UNIV DENMARK TECH DTU (DK) | 2019-07-03 | — | — | EP | disclosed |
| US-20180219257-A1 | ALUMINUM-ION BATTERY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-08-02 | — | — | US | disclosed |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | UNIV DENMARK TECH DTU (DK) | 2017-11-30 | — | — | US | disclosed |
| EP-2473277-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | Technical University of Denmark (DK) | 2012-07-11 | — | — | EP | disclosed |
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2011-03-17 | — | — | US | disclosed |
| WO-2011026860-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALIZED IONIC LIQUID | TECHNICAL UNIVERISTY OF DENMARK (DK) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | RBM22, HNRNPUL2, HNRNPUL1 | FDPS 4267/4885MEN1 1762/4885HSP90AA1 573/4885 |
| US-20110065950-A1 | PALLADIUM CATALYST SYSTEM COMPRISING ZWITTERION AND/OR ACID-FUNCTIONALYZED IONIC LIQUID | PDCD2L, PCCA, PDK2 | FDPS 72/4885MEN1 1283/4885HSP90AA1 4752/4885 |
| US-20170341067-A1 | Palladium Catalyst System Comprising Zwitterion And/Or Acid-Functionalyzed Ionic Liquid | PDCD2L, PCCA, PDK2 | FDPS 72/4885MEN1 1283/4885HSP90AA1 4752/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | FDPS 2983/4885MEN1 3452/4885HSP90AA1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.